AmpliPhi Biosciences Corporation (APHB)

0.323502 +0.0013 (+0.404%)

IEX Real-Time Price

October 19, 2018 EST.

NYSE American : Healthcare

Prev Close 0.3222

Price Open 0.34

Volume: 843,159

Avg Volume: 883,202

Market Cap: 5.33M

P/E Ratio -0.42

52 Wk Range 0.31-2.05



APHB Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
16.03M
1.43M
9.20
8.94%

2018-09-14
16.03M
1.07M
8.58
6.70%

2018-08-31
16.03M
1.06M
9.09
6.62%

2018-08-15
16.03M
821,241
10.14
5.12%




APHB Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-09
Q2 2018
N/A
-0.20 (2)
-0.19
0.01

2018-05-21
Q1 2018
N/A
-0.19 (1)
0.00
0.00

2018-05-15
Q1 2018
AMC
-0.19 (2)
-0.24
-0.05

2018-03-26
Q4 2017
N/A
-0.36 (2)
0.00
0.00

News

AmpliPhi Biosciences Announces Closing of Public Offering (2018-10-16 16:10 Business Wire)

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously anno…

 


Statistics

Shares Outstanding: 16.47M

Top 15 Institution Percent: 17.90

Price To Sales: 265.30

Price To Book: 0.64

Revenue: 38000

Gross Profit: N/A

Cash: 7.73M

Debt: N/A

Return On Assets: -69.45

Return On Equity: -102.36

Profit Margin: N/A

Price History

Beta: 2.06

50-day Moving Avg: 0.91

200-day Moving Avg: 1.12

YTD Change: -67.97

5-day Change: -0.83

1-month Change: -62.82

3-month Change: -70.32

6-month Change: -72.81

1-year Change: -75.12

Revenue Per Share: 0.00

Revenue Per Employee: 1118.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: AmpliPhi Biosciences Corporation

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.ampliphibio.com

Ampliphi Biosciences Corp engages in discovery, development, and commercialization of novel phage therapeutics.